Mitsubishi UFJ Asset Management Co. Ltd. Has $1.28 Million Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Mitsubishi UFJ Asset Management Co. Ltd. reduced its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 23.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 141,160 shares of the medical instruments supplier's stock after selling 43,070 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.35% of AngioDynamics worth $1,282,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Segall Bryant & Hamill LLC boosted its holdings in AngioDynamics by 55.3% during the fourth quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier's stock valued at $12,963,000 after purchasing an additional 503,713 shares in the last quarter. American Century Companies Inc. lifted its position in shares of AngioDynamics by 22.1% during the 4th quarter. American Century Companies Inc. now owns 67,942 shares of the medical instruments supplier's stock worth $622,000 after buying an additional 12,306 shares during the period. Intech Investment Management LLC acquired a new stake in AngioDynamics in the 4th quarter valued at $152,000. Royce & Associates LP grew its position in AngioDynamics by 13.5% in the fourth quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier's stock valued at $10,254,000 after acquiring an additional 133,312 shares during the period. Finally, First Eagle Investment Management LLC raised its stake in AngioDynamics by 4.1% during the fourth quarter. First Eagle Investment Management LLC now owns 410,335 shares of the medical instruments supplier's stock worth $3,759,000 after acquiring an additional 16,221 shares in the last quarter. Institutional investors own 89.43% of the company's stock.

Insider Activity at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares of the company's stock, valued at $514,767.27. This represents a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $16.00 target price (up previously from $15.00) on shares of AngioDynamics in a research note on Monday.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO traded up $0.20 during mid-day trading on Monday, hitting $9.31. 697,672 shares of the stock were exchanged, compared to its average volume of 573,078. AngioDynamics, Inc. has a twelve month low of $5.47 and a twelve month high of $13.50. The stock's fifty day simple moving average is $10.10 and its two-hundred day simple moving average is $8.90. The company has a market cap of $376.74 million, a P/E ratio of -1.65 and a beta of 0.52.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. The firm had revenue of $72.00 million during the quarter, compared to analysts' expectations of $70.30 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. AngioDynamics's quarterly revenue was down 4.3% compared to the same quarter last year. As a group, equities research analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.